Copd Therapeutics in Major Developed Market Analysis and Treatment, 2021: Hexa Reports

Hexa Reports

Market Research Reports and Insightful Company Profiles

COPD Therapeutics in Major Developed Market Size,

Share, Growth, Treatment, Analysis, Symptoms, Emerging

Trends and Opportunities to 2021

COPD Therapeutics in Major Developed Markets to 2021 - Emergence of Addition-in-Class and First-inClass Products Offsets Sales Erosion of Leading Brands

Summary

Chronic Obstructive Pulmonary Disease (COPD) is a progressive disorder associated with chronic

inflammation of the airways and lungs. Persistent breathing difficulties and repeated exacerbations of

COPD symptoms make the disease one of the leading causes of morbidity, and the fifth-leading cause of

death in the world.

Browse Detail Report With TOC @

http://www.hexareports.com/report/copd-therapeutics-in-major-developed-markets/details

COPD is linked to cumulative exposure to risk factors, primarily tobacco smoke, but also environmental

pollutants. The COPD marketed products landscape consists of pharmacological therapies aimed at

managing the symptoms associated with COPD, although none of the available therapies have been

shown to modify long-term disease progression.

Hexa Reports

Market Research Reports and Insightful Company Profiles

There are currently 203 products in active development, excluding four with an unknown stage of

development. Although many of the targets identified in the pipeline are well established in the

management of COPD, there are some novel, first-in-class targets. This reflects the growing

understanding of the underlying mechanisms that characterize the disease.

Scope

The COPD market has benefited from notable additions over recent years.

 Which classes of drug dominate the market?

 What additional benefits have newly approved therapies brought to market?

 How do the leading marketed therapies compare clinically?

 The pipeline contains a range of molecule types and molecular targets, including those that are well

established in COPD, and novel, first-in-class...